Atterx BioTherapeutics
Atterx, based in Wisconsin, pioneers innovative therapeutics to combat antibiotic-resistant bacteria globally.
Founded
2001Atterx, based in Wisconsin, pioneers innovative therapeutics to combat antibiotic-resistant bacteria globally.
Atterx BioTherapeutics, founded in Madison, Wisconsin, is dedicated to developing innovative therapeutics to address the global crisis of antibiotic-resistant bacteria. The company aims to introduce novel solutions to prevent and treat infections that no longer respond to conventional antibiotics. Atterx's core technology offers a new method to eliminate unwanted and multi-drug resistant bacteria. Their primary products include C-1205, targeting catheter-associated urinary tract infections, and GN-4474, aimed at combating gram-negative bacterial infections.
Notable figures affiliated with Atterx include experts in microbiology and pharmacology who contribute to its cutting-edge research and development. The company operates out of the MG&E Innovation Center in the University Research Park, fostering a collaborative environment for scientific advancement. Key achievements include the development of their proprietary technologies and securing initial funding to propel their research. Atterx's impact lies in its potential to revolutionize the treatment of antibiotic-resistant infections, addressing a critical and growing public health threat.
Companies similar to Atterx BioTherapeutics include X-Biotix Therapeutics, Nexcida Therapeutics, Armata Pharmaceuticals and Endolytix.
Atterx BioTherapeutics was founded in 2001.
Atterx BioTherapeutics' headquarters is located in Madison, WI, US.
As of Jan 17, 2023, Atterx BioTherapeutics has disclosed funding of $6.2M (USD). Undisclosed round amounts are excluded.
Atterx BioTherapeutics has 7 employees as of Feb 4, 2024.
Endolytix
